Drug Policy:
Yondelis™ (trabectedin)

I. PURPOSE

To define and describe the accepted indications for Yondelis (trabectedin) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR

2. When health plan Exchange coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR
3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways when applicable, otherwise shall follow NCH drug policies AND

4. Continuation requests of previously approved, non-preferred medication are not subject to this provision AND

5. When available, generic alternatives are preferred over brand-name drugs.

B. **Soft Tissue Sarcoma**
   1. The member has unresectable or metastatic soft tissue sarcoma (Leiomyosarcoma, liposarcoma, and translocation-related sarcomas) AND
   2. Yondelis (trabectedin) is being used as a single agent AND
   3. The member had disease progression with prior anthracycline-based chemotherapy.

C. **Uterine Sarcoma**
   1. The member has unresectable or metastatic uterine leiomyosarcoma AND
   2. Yondelis (trabectedin) is being used as single agent for members with disease progression with prior anthracycline-based chemotherapy.

III. **EXCLUSION CRITERIA**

A. Yondelis (trabectedin) is being used after disease progression with Yondelis.

B. Yondelis (trabectedin) use in sarcomas other than leiomyosarcoma, liposarcoma and translocation-associated sarcomas.
   [In the phase III TSAR trial, patients with non-liposarcoma/LMS histotypes, trabectedin had no objective tumor responses relative to the liposarcoma/LMS group (0 versus 19 percent) and had similar PFS to those receiving best supportive care (median 1.8 versus 1.5 months). In contrast, for those with liposarcoma/LMS, trabectedin demonstrated improved PFS relative to best supportive care (median 5.1 versus 1.4 months)].

C. Concurrent use with DTIC (dacarbazine) or other chemotherapy.

D. Dosing exceeds single dose limit of Yondelis (trabectedin) 1.5 mg/m².

E. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. **MEDICATION MANAGEMENT**

A. Please refer to the FDA label/package insert for details regarding these topics.

V. **APPROVAL AUTHORITY**

A. Review – Utilization Management Department

B. Final Approval – Utilization Management Committee

VI. **ATTACHMENTS**

A. None

VII. **REFERENCES**


